Insider · CIK 0001801842

Hall Ashley

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001801842

Forms 4 and 5

Insider transactions

18 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-19	GPCRStructure Therapeutics Inc.A Award	Chief Development Officer	AAward	+47.7K sh	—	—	155,187
2026-03-19	GPCRStructure Therapeutics Inc. · Employee Stock Option (right to buy)A Award	Chief Development Officer	AAward	+59.1K sh	—	—	59,073
2026-03-03	GPCRStructure Therapeutics Inc.F Tax Payment	Chief Development Officer	FTax Payment	−4,836 sh	$20.99	−$102K	107,481
2025-11-20	GPCRStructure Therapeutics Inc. · American Depositary SharesA Award	Chief Development Officer	AAward	+237 sh	—	—	462
2025-09-18	GPCRStructure Therapeutics Inc.F Tax Payment	Chief Development Officer	FTax Payment	−6,021 sh	$7.74	−$46.6K	112,317
2025-05-20	GPCRStructure Therapeutics Inc. · American Depositary SharesA Award	Chief Development Officer	AAward	+225 sh	—	—	225
2025-03-15	GPCRStructure Therapeutics Inc.A Award	Chief Development Officer	AAward	+51K sh	—	—	118,338
2025-03-15	GPCRStructure Therapeutics Inc. · Employee Stock Option (right to buy)A Award	Chief Development Officer	AAward	+124K sh	—	—	124,032
2024-09-18	GPCRStructure Therapeutics Inc.A Award	Chief Development Officer	AAward	+67.3K sh	—	—	67,290
2024-09-18	GPCRStructure Therapeutics Inc. · Share option (right to buy)A Award	Chief Development Officer	AAward	+82.9K sh	—	—	82,890
2023-08-28	OKUROnKure Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+15.6K sh	$1.80	+$28.1K	55,225
2023-08-28	OKUROnKure Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−15.6K sh	$6.28	−$98.1K	39,600
2023-08-28	OKUROnKure Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−15.6K sh	—	—	109,375
2022-12-09	OKUROnKure Therapeutics, Inc. · Stock option (right to buy)A Award	Chief Development Officer	AAward	+125K sh	—	—	125,000
2021-11-12	OKUROnKure Therapeutics, Inc.A Award	Chief Development Officer	AAward	+30K sh	—	—	30,000
2021-11-12	OKUROnKure Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+180K sh	—	—	180,000
2021-01-28	ESPREsperion Therapeutics, Inc.A Award	Chief Development Officer	AAward	+7,000 sh	—	—	22,500
2021-01-28	ESPREsperion Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+31K sh	—	—	31,000

Recent filings

Accepted (ET)
Mar 234
Hall Ashley0001801842-26-000003
SEC(opens sec.gov)
Mar 54
Hall Ashley0001801842-26-000002
SEC(opens sec.gov)
Sep 224
Hall Ashley0001801842-25-000004
SEC(opens sec.gov)
Mar 184
Hall Ashley0001415889-25-008554
SEC(opens sec.gov)
Sep 204
Hall Ashley0001415889-24-023794
SEC(opens sec.gov)
Aug 294
Hall Ashley0001209191-23-047626
SEC(opens sec.gov)
Dec 134
Hall Ashley0001209191-22-061038
SEC(opens sec.gov)
Nov 154
Hall Ashley0001209191-21-064587
SEC(opens sec.gov)
Jan 294
Hall Ashley0001628280-21-001177
SEC(opens sec.gov)

Companies

Address

C/O STRUCTURE THERAPEUTICS INC. 601 GATEWAY BLVD., SUITE 900

SOUTH SAN FRANCISCO, CA, 94080